Moderna, Inc. $MRNA Shares Sold by Banco Bilbao Vizcaya Argentaria S.A.

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. sold 54.4% of its stake in Moderna, reducing its holdings to 153,922 shares valued at approximately $4.4 million.
• Analysts have recently downgraded Moderna's stock price target, with Barclays reducing it from $40.00 to $31.00, alongside a mixed outlook from other analysts.
• Moderna's recent earnings report showed a loss of ($2.13) per share on revenue of $142 million, marking a 41.1% year-over-year decline in revenue.

Banco Bilbao Vizcaya Argentaria S.A. lessened its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 54.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 153,922 shares of the company's stock after selling 183,308 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Moderna were worth $4,377,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Theleme Partners LLP raised its stake in shares of Moderna by 1.0% in the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock valued at $303,819,000 after acquiring an additional 72,028 shares during the period. Invesco Ltd. raised its stake in shares of Moderna by 17.5% in the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock valued at $166,801,000 after acquiring an additional 877,162 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Moderna by 8.7% in the 4th quarter. The Manufacturers Life Insurance Company now owns 3,341,924 shares of the company's stock valued at $138,957,000 after acquiring an additional 267,990 shares during the period. Northern Trust Corp raised its stake in shares of Moderna by 5.4% in the 1st quarter. Northern Trust Corp now owns 3,119,626 shares of the company's stock valued at $88,441,000 after acquiring an additional 160,572 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Moderna by 12.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock valued at $74,557,000 after acquiring an additional 285,662 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MRNA shares. Barclays cut their target price on shares of Moderna from $40.00 to $31.00 and set an "equal weight" rating on the stock in a research note on Monday, August 4th. Citigroup began coverage on shares of Moderna in a research note on Friday, August 1st. They set a "neutral" rating and a $40.00 price target on the stock. Evercore ISI set a $32.00 price objective on shares of Moderna in a report on Friday, August 1st. JPMorgan Chase & Co. set a $26.00 price objective on shares of Moderna in a report on Friday, August 1st. Finally, William Blair reiterated a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, sixteen have issued a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, Moderna has an average rating of "Hold" and a consensus target price of $43.59.

Moderna Price Performance

Shares of MRNA stock opened at $26.89 on Thursday. The company's fifty day moving average price is $29.19 and its two-hundred day moving average price is $29.24. The firm has a market capitalization of $10.46 billion, a P/E ratio of -3.57 and a beta of 1.83. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $88.59.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company's revenue was down 41.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.